Latest Product Pipeline News

Western Gold Resources has locked in critical approvals and agreements to accelerate production at its Gold Duke Project in Western Australia, backed by an updated resource estimate and a binding toll milling contract.

Advanced Braking Technology Ltd has reported a record half-year performance for 1H26, driven by strong demand for its SIBS Failsafe braking systems and progress in autonomous braking technology.

Austral Resources Australia Ltd has swung from a $22.6 million loss in 2024 to an $11.9 million profit in 2025, driven by strategic asset sales and acquisitions. The company is now poised to accelerate copper production with a major capital raise and new mining leases.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

AVITA Medical closed 2025 with steady revenue growth and over 80% gross margin, setting the stage for a confident revenue forecast of up to US$85 million in 2026. The company also secured a new debt facility with improved terms, underpinning its growth ambitions.

Cochlear Limited posted a modest 1% increase in sales revenue for the half year ending December 2025, while underlying net profit fell 9%, impacted by cloud computing costs and a slower-than-expected Nexa System rollout. The company maintains its dividend and outlines cautious FY26 guidance.

CAR Group has reported strong first-half results for FY26, with double-digit revenue and earnings growth across all key regions, underpinned by strategic AI investments and expanding market presence.

Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.

Orthocell Ltd reports steady progress in commercialising its nerve repair product Remplir in the US, with sales growth, expanded distributor networks, and manufacturing upgrades underpinning its path to profitability.

Weebit Nano has landed its largest customer yet with Texas Instruments licensing its ReRAM technology, while achieving key technical milestones and doubling its revenue guidance for FY26.